Listening to astronomy

Astronomy started out as a purely visual science, but with todays electronics and techniques, you can also hear astronomy. It used to be that you to take classes, or else had to be in the right place at the right time to hear a lecture on astronomy. But, thanks to the Internet, there are many resources for hearing astronomy online.

Of course, you can hear astronomy information right here on this website, via the 90-second EarthSky interviews. You can also hear 22 minutes of science and music each week from EarthSky on the EarthSky 22 podcast.

And there is AstronomyCast with Frasier Cain and Pamela Gay.

But what really got me to thinking about this was the Silicon Valley Astronomy Lectures, a series of audio podcasts by eminent astronomers, from the Astronomical Society of the Pacific. Among the lectures are Dr. Jeff Moore (NASA Ames Research Center): New Horizons at Jupiter (and Some Saturn News); Dr. David Morrison (NASA Ames Research Center): Taking a Hit: Asteroid Impacts and Evolution; Dr. Dana Backman (SETI Institute and Astronomical Society of the Pacific): A Ringside Seat to the Formation of Planets; and Dr. David Grinspoon (Denver Museum of Nature and Science): Comparing Worlds: Climate Catastrophes in the Solar System.

You may already be familiar with Science at NASA, and there are also podcasts from the main NASA site, as well as the Jet Propulsion Laboratory (JPL).

Well, that was just a start. I did a little online searching and was amazed to find all the places you can hear astronomy. You might want to do a little searching for yourself. If the links above dont give you enough to listen to, here are a few more.

I also found the Astronomy Media Player, which is actually web page with links to a number of astronomy and space podcasts from around the world.

If you have time to listen to more than this, Im sure a little searching will turn up much more. What are your favorite links? Tell us in the comments below.

See original here:

Listening to astronomy

Fujitsu to build software robot to pass college entrance exams

Fujitsu said Monday it will lead a project to create artificial intelligence capable of passing the math portion of the entrance exams to one of Japan's top universities.

The company's research division said its goal is to make software by 2021 that can complete exactly the same math test that hopeful teenagers take when applying to Tokyo University, or "Todai," known for its grueling entrance requirements. The project will need to process text and formulas meant for human eyes, extract the math problems and convert them into a form meant for computers, and then solve the problems at the level of Japan's top high school students.

"Each of these steps still poses major theoretical and practical problems, and for each one, the solution will involve an appropriate combination of various technologies," Fujitsu said in a statement.

Sample questions from previous tests posted online show world problems that must be solved in consecutive stages, geometry problems that refer to drawn diagrams, and problems that require the application of specific equations memorized by test takers.

Currently, only about half of the problems on some such tests can be solved by computers alone, even using advanced algorithms, the company said. The exam problems will also have to be solved quickly and without mistakes.

A software robot that could pass university entrance tests would strike a major emotional chord in the country, where the tests are a major part of society. Most students attend cram schools for years to prepare for the tests, in addition to their normal schools, and often become full time cram-school students if they fail to get into the university of their choice. Sample problems are published in national newspapers each year, and TV stations cover the posting of results outside the buildings of top universities.

Fujitsu said it hopes to use technology developed in the project to create intelligent systems that are capable of performing advanced analysis on themselves, for self-optimization and similar tasks.

The electronics conglomerate will oversee the math portion of a larger project announced last year that aims to pass all subjects of the entrance exams at the university, called "Can a robot enter Todai?" The project is being run by the National Institute of Informatics, a publicly funded software research foundation.

Its stated goal is to create software capable of achieving a strong score on the tests by 2016, then get marks high enough to win entrance by 2021. It was founded as a way to unify the increasingly diverse areas of study in artificial intelligence.

Any robots that do wish to take the entrance exams should be careful, as calculators and other electronics are forbidden by the university.

Continue reading here:

Fujitsu to build software robot to pass college entrance exams

Rocket Fuel Announces Audience Accelerator

REDWOOD SHORES, CA--(Marketwire - Sep 10, 2012) - Rocket Fuel, the leading provider of artificial intelligence advertising solutions for digital marketers, today announced the availability of Audience Accelerator, a full-service audience extension platform that helps publishers and vertical networks create new exclusive advertising packages based on their unique audiences.

Key Facts:

How Audience Accelerator is Unique in the Marketplace:

Quotes:

Resources:

About Rocket Fuel:

Rocket Fuel is the leading provider of artificial intelligence advertising solutions that transform digital media campaigns into self-optimizing engines that learn and adapt in real-time, and deliver outstanding results from awareness to sales. Recently awarded #22 in Forbes Most Promising Companies in America list, over 700 of the world's most successful marketers trust Rocket Fuel to power their advertising across display, video, mobile, and social media. Founded by online advertising veterans and rocket scientists from NASA, DoubleClick, IBM, and Salesforce.com, Rocket Fuel is based in Redwood Shores, California, and has offices in fifteen cities worldwide including New York, London, Toronto, and Hamburg.

2012 Rocket Fuel Inc. All rights reserved. Rocket Fuel Inc. and Audience Accelerator are registered trademark of Rocket Fuel Inc. in the U.S. and/or other countries. All other trademarks are the property of their respective owners.

Read more:

Rocket Fuel Announces Audience Accelerator

Advertising That Learns: Eric Porres of Rocket Fuel to Present at Advertising Week DC 2012

REDWOOD SHORES, CA--(Marketwire - Sep 10, 2012) - Rocket Fuel, the leading provider of artificial intelligence advertising solutions for digital marketers, today announced that CMO Eric Porres will deliver a keynote presentation at Advertising Week DC (ADWKDC). Porres will deliver a presentation titled "Advertising that Learns" on Tuesday, September 11th at 10:45 am at Federal Hall at The Washington Plaza Hotel.

News Facts:

Resources: About ADWKDC About Rocket Fuel Follow Rocket Fuel on Twitter Follow Rocket Fuel on Facebook Read the Rocket Fuel Blog

About Rocket Fuel: Rocket Fuel is the leading provider of artificial intelligence advertising solutions that transform digital media campaigns into self-optimizing engines that learn and adapt in real-time, and deliver outstanding results from awareness to sales. Recently awarded #22 in Forbes Most Promising Companies in America list, over 700 of the world's most successful marketers trust Rocket Fuel to power their advertising across display, video, mobile, and social media. Founded by online advertising veterans and rocket scientists from NASA, DoubleClick, IBM, and Salesforce.com, Rocket Fuel is based in Redwood Shores, California, and has offices in fifteen cities worldwide including New York, London, Toronto, and Hamburg.

2012 Rocket Fuel Inc. All rights reserved. Rocket Fuel Inc. is a registered trademark of Rocket Fuel Inc. in the U.S. and/or other countries. All other trademarks are the property of their respective owners.

See the original post here:

Advertising That Learns: Eric Porres of Rocket Fuel to Present at Advertising Week DC 2012

PFS Aerospace Announces First You-in-Space Public Participation Space Program Using the First "Launch Anywhere/Recover …

SAN FRANCISCO--(BUSINESS WIRE)--

PFS Aerospace (http://www.pfs-aerospace.com) announced today that they have developed one of the lowest-cost launch-and-return spacecraft systems available in the market. Per the new technology, PFS is now offering the first web-based click-to-buy personal space launch service in the world!

The PFS personal satellites and spacecraft have been developed with a technology consortium focused on the production of low-cost-easy-orbit personal satellite systems for community service groups. The first projects are focused on emergency communications, regional communications, toxin sensing and space debris clean-up. PFS has developed unique technologies to improve the process, reduce costs and ease logistics.

PFS has developed the first "Launch Anywhere/Recover Anywhere" spacecraft system. One such system can be legally launched from a boat in San Francisco Bay.

Now PFS is offering individuals and companies access to space at ground-breaking prices for their first BETA CUSTOMERS. Potential beta customers can buy a launch right on the PFS website located at http://www.pfs-aerospace.com.

The launch service includes a video of an in-space video screen playing a 3 minute video of you saying "hello" (or whatever you want to put in your video) from the edge of space plus your logo or picture in the lower right of the video that PFS makes for you. The deliverable to you is an .MP4 video of your digital trip to space. You email PFS your 3 minute .MP4 video for the launch. PFS will prep, launch & return the spacecraft.

So, to say it another way: You send PFS a movie of you, PFS sends it into space, plays it in space and makes a movie of you, on the screen, in space. You get PFSs movie, of your movie, with the Earth, from space, in the background. You can post the movie on your website, send it to your friends and impress your family. This is not a special effects movie. This is you, on a movie screen, in space! PFS has the launch vehicles. (For orbital trips and other device capabilities prices are higher, please contact PFS for a quote for capabilities beyond "prep-launch-return".) Delivery times are contingent on weather and staff availability per launch.

See more here:

PFS Aerospace Announces First You-in-Space Public Participation Space Program Using the First "Launch Anywhere/Recover ...

Bombardier Aerospace puts 'pause' on discretionary spending to preserve cash

By Ross Marowits, The Canadian Press

MONTREAL - Bombardier's aerospace division is putting a "pause" on discretionary spending at least until January to preserve cash for two key aircraft development programs.

In a memo to employees, the Montreal-based transportation giant said it is suspending most new hirings, cancelling off-site meetings, cutting all funding for Christmas parties and even suspending most travel.

Other measures include reducing or delaying spending on consultants, suspending most training, and stopping any office renovations. All capital spending will have to receive senior management approval.

Spokeswoman Haley Dunne says the missive sent last week from finance vice-president Mairead Lavery was meant to remind employees to be more prudent about what they're spending on during the company's peak period of investment.

"We're halfway through the year so it's just time to make sure that people are aware that they need to be focusing on our priorities," she said in an interview.

Lavery told employees that "performance in cash generation was not in line with budget for the first six months of the year" and that the move was needed because Bombardier has limited control over when it receives cash from customers.

The company will fill positions required for the development programs, but non-essential positions will remain vacant until after January.

Bombardier Aerospace (TSX:BBD-B.TO - News) last put a freeze on discretionary spending in 2009.

The world's third-largest aircraft manufacturer is in the midst of several development projects, notably the new CSeries commercial aircraft set to begin deliveries the end of 2013 and the Learjet 85 business jet, also set to be delivered next year.

See the original post here:

Bombardier Aerospace puts 'pause' on discretionary spending to preserve cash

ST Aerospace Liquidates Singapore British Engineering

Singapore, 10 September 2012 ST Aerospace today announced its 51%-owned subsidiary, Singapore British Engineering Pte Ltd (SBE), has commenced Members Voluntary Winding Up. SBE, a joint venture between ST Aerospace and BAE Systems plc (BAE Systems), was set up for the marketing of BAE Systems avionics and defence products in Singapore.

Shareholders of SBE had approved the appointment of Andrew Grimmett and Lim Loo Khoon of Messrs Deloitte & Touche Financial Advisory Services Pte Ltd as Joint and Several Liquidators for the purpose of the liquidation of SBE.

The decision to liquidate SBE was mutually agreed upon between ST Aerospace and BAE Systems, and a result of ongoing engagement and reviews between the partners to better support the latters business growth in the region through ST Aerospaces global network. Existing SBE contracts are novated to ST Aerospaces wholly owned subsidiary ST Aerospace Supplies Pte Ltd (STA Supplies) to ensure continual support to customers, and STA Supplies will work closely with BAE Systems to explore further collaboration opportunities.

The voluntary liquidation of SBE is not expected to have any material impact on the consolidated net tangible assets per share and earnings per share of ST Engineering for the current financial year.

ST Aerospace (Singapore Technologies Aerospace Ltd) is the aerospace arm of ST Engineering. Operating a global MRO network with facilities and affiliates in the Americas, Asia Pacific and Europe, it is the worlds largest commercial airframe MRO provider with a global customer base that includes leading airlines, airfreight and military operators. ST Aerospace is an integrated service provider that offers a spectrum of maintenance and engineering services that include airframe, engine and component maintenance, repair and overhaul; engineering design and technical services; and aviation materials and management services, including Total Aviation Support. ST Aerospace has a global staff strength of more than 8,000 engineers and technical specialists. Please visit http://www.staero.aero.

Visit link:

ST Aerospace Liquidates Singapore British Engineering

Bombardier aerospace staff told to cut discretionary spending

TORONTO (Reuters) - Bombardier Inc has told staff in its aerospace unit to suspend discretionary spending for the rest of the year so that the Canadian company can keep cash for its costly C-Series and Learjet 85 aircraft development programs. The world's third-biggest plane maker said in an internal memo sent to more than 35,000 aerospace division staff on September 5 that cash must be ...

Read the original:

Bombardier aerospace staff told to cut discretionary spending

Purina Animal Nutrition and Science Supplements Announce Strategic Partnership

ST. LOUIS, MO--(Marketwire - Sep 10, 2012) - Purina Animal Nutrition announced it has formed a strategic partnership with U.K.-based Science Supplements that will allow it to expand into the U.S. horse supplement market and continue to provide premium animal nutrition solutions. The partnership will fuel future product launches that include industry-leading research and the highest quality ingredients, coupled with technology, to create unique, value-added products for horse owners.

Science Supplements produces a range of products, from hydration to joint supplements, which undergo extensive research and development before being released on the market. By combining the company's deep insights with the extensive research program at the Purina Animal Nutrition equine research facility in Gray Summit, Mo., the partnership will provide U.S. horse owners with access to products proven to be effective.

"Our goal for entering the supplement category was to offer products made using the same stringent standards that we've used on the feed side of our business for more than 100 years," said David Hoogmoed, executive vice president and chief operating officer, feed, Purina Animal Nutrition. "We believe Science Supplements is to supplements as Purina Animal Nutrition is to feed."

Both companies believe in the slow process of research and development in order to supply only the finest quality ingredients, backed by product trials.

"This relationship is forging new inroads to the U.S. supplement market and is not only supply of product but about joint development and education," says Dr. David Marlin, CEO of Science Supplements. "The end goal is to provide products backed by extensive research and development for the animals we work with so closely."

Horse owners can expect to see new horse supplement offerings from Purina Animal Nutrition later this year.

About Purina Animal Nutrition Purina Animal Nutrition LLC is a national organization serving producers, animal owners and their families through more than 4,700 local cooperatives, independent dealers and other large retailers across the United States. Driven by an uncompromising commitment to animal excellence, Purina Animal Nutrition is an industry innovator, offering America's leading brands of complete feeds, supplements, premixes, ingredients and specialty technologies for the livestock and lifestyle animal markets.

Headquartered in Shoreview, Minn., Purina Animal Nutrition LLC is a wholly owned subsidiary of Land O'Lakes, Inc.

About Science Supplements Science Supplements Ltd. produces a range of unique and efficacious products for the equine market using cutting-edge science, the latest developments in research and the finest quality active ingredients. Science Supplements Ltd. products are formulated by Dr. David Marlin, working in conjunction with the best international experts in different nutrition related fields. Science Supplements undertakes both laboratory, clinical and field trials to ensure that these products are both highly effective and safe.

Original post:
Purina Animal Nutrition and Science Supplements Announce Strategic Partnership

The Outdoors Hates You: More New Tick-Borne Diseases (ICAAC 1)

This week Im at ICAAC (the Interscience Conference on Antimicrobial Agents and Chemotherapy), a massive infectious-disease and drugs meeting that is sponsored every year by the American Society for Microbiology. ICAAC is an unabashed scary-disease geekgasm, the kind of meeting at which the editor of a major journal tweets from one room, Modern medicine will come to a halt in India because of catastrophic multi-drug resistance while a microbiologist alerts from another: Rat lungworm traced to salads on a Caribbean cruise. Snails had apparently gotten to the greens.

Good times.

Meanwhile, I was learning more about ticks.

The news last week was of a new tick-borne illness recently identified in Missouri, and of how it demonstrates the way that tick-borne infections are under-appreciated by medicine and public health, and even more by the general public. In addition to the new Heartland virus, I mentioned two other tick-borne diseases that had been identified in the past two years.

It turns out, though, that was an under-count. The news Sunday from ICAAC is that tick-related illnesses are even more common than they appear.

Dr. Bobbi Pritt, the laboratory director of the Mayo Clinic in Rochester, Minn., unfolded a disease detective story that started in the summer of 2009 with two men who liked the outdoors, and two astute lab technicians. The men, a 54-year-old and a 23-year-old who had both been out in the woods in Wisconsin, had fevers, fatigue and headaches, and a history of tick bites; the 23-year-old, who had received a lung transplant for cystic fibrosis, was more seriously ill and had to be hospitalized. The technicians noted that the mens disease was most like erlichiosis but the tick that carries that tick-borne illness is not present in the upper Midwest. Months later after the Centers for Disease Control and Prevention had sent a pair of investigators, after involving epidemiologists from the US military who had been studying illness in the residents of bases nationwide, after trapping mice and grinding up hundreds of ticks the group realized they had found a new tick-borne illness. It was an Erlichia though it is so new that it does not yet have a name but it was carried by a tick species that had never been associated with that organism before. Forty-two people have been sickened by it so far. This is not a benign disease, Pritt warned.

Meanwhile, Dr. Peter Krause, a senior research scientist at the Yale schools of medicine and public health, described yet another formerly unknown tick-borne disease, one that is more like Lyme disease but is caused by a newly identified relative of the Lyme organism called Borrelia miyamotoi. The illness that results is a severe and sometimes fatal relapsing fever. But unlike other relapsing fevers already known to occur in the western United States, this one is carried by a different range of tick species: the hard-bodied ticks that are primarily in the eastern US and are responsible for transmitting Lyme, erlichiosis and anaplasmosis. So far, Krause said, this new disease has been most studied in humans in Russia but ticks carrying B. miyamotoi have already been identified in the United States, in ticks and mice in the Northeast and upper Midwest.

Then, Dr. Gary Wormser of New York Medical College warned that a third tick-borne illness, deer tick virus formerly known to affect only deer is now emerging as a human pathogen. Two cases of encephalitis caused by it have been recorded. Wormser described a third, tragic case that he has not yet published: a 77-year-old man from upstate New York who already had several chronic illnesses was bitten by a tick in October 2010, developed a fever and lethargy a month later, slid into a coma and died 8 months later, having never regained consciousness.

Finally, Dr. Barbara Herwaldt of the CDC reminded us that, even if these stories frighten you enough to never leave your house, you are still at risk of a tick-borne disease. To date, 159 people the tip of the iceberg, she said have been diagnosed with the tick-borne illness babesiosis after receiving a blood transfusion. Because of the lag between bite and symptoms, and because the symptoms of babesiosis like all tick-borne diseases could be caused by so many other things, infected donors are not successfully screened out by blood banks. And because there is no FDA-approved test for babesiosis not just a test for blood, but not even a diagnostic test to prove infection in a patient blood banks and even physicians are unable to say with certainly when someone is a risk and should abstain from donating.

Visit link:
The Outdoors Hates You: More New Tick-Borne Diseases (ICAAC 1)

Dr. Tom Maniatis honored with 2012 Lasker-Koshland Special Achievement Award in Medical Science

Public release date: 10-Sep-2012 [ | E-mail | Share ]

Contact: Karin Eskenazi ket2116@columbia.edu 212-342-0508 Columbia University Medical Center

NEW YORK (September 10, 2012) Tom Maniatis, PhD, the Isidore S. Edelman Professor of Biochemistry and chair of the Department of Biochemistry and Molecular Biophysics at Columbia University Medical Center, is to receive the 2012 Lasker-Koshland Special Achievement Award in Medical Science. Dr. Maniatis is known for both his research on the mechanisms of gene regulation and his Molecular Cloning Manual. Dr. Maniatis will receive the award on Sept. 21 in New York City.

"I am deeply honored to receive the Lasker Special Achievement Award in Medical Science," said Dr. Maniatis. "I became a scientist because of the excitement of making discoveries, but to see the impact of these discoveries on the treatment of human disease has been particularly gratifying."

"Tom Maniatis' work is the quintessential example of the path from basic science to clinical applications," said Lee Goldman, MD, executive vice president of Columbia University and dean of the faculties of health sciences and medicine at Columbia University Medical Center. "His cloning manual is used by researchers worldwide, while his research contributions are at the foundation of current thinking about genetics."

In 1980 James Watson, PhD, director of Cold Spring Harbor Laboratory (CSHL), asked Maniatiswho was on the Harvard faculty at the timeto teach new genetic engineering techniques during a summer course at CSHL and then to produce a manual. The resultant Molecular Cloning Manualpublished in 1982 and often referred to as "the Bible" by students and researcherscontained practically every technique biologists needed to manipulate DNA.

Scientists could now identify genes that cause disease and then produce new drugs such as human insulin; and the techniques were indispensable for the success of the Human Genome Project. Dr. Maniatis' laboratory developed many of the techniques in the manual, which he coauthored with his postdoctoral fellow Ed Fritsch, PhD, and Joe Sambrook, PhD, the scientific director at CSHL.

Using the new techniques, Dr. Maniatis was the first to isolate a human gene and to use the cloned gene to identify deletion and substitution mutations that cause disease. The gene beta globin, for example, is part of the hemoglobin complex, and the mutations Dr. Maniatis identified cause a blood disease called beta thalassemia.

Maniatis also created the first complete human "genomic" DNA librarya collection of DNA containing every human genewhich made it possible to isolate and study any human gene. As with his genetic engineering techniques, Maniatis freely shared this library with other researchers.

In other research, Dr. Maniatis and his students uncovered important details of how information in genes is turned into proteins, including the mechanisms of transcription and RNA splicing.

Here is the original post:
Dr. Tom Maniatis honored with 2012 Lasker-Koshland Special Achievement Award in Medical Science

Two Columbia Professors Win Lasker Foundation Awards for Their Work in Biological Sciences

Two Columbia professors have won prestigious Lasker Foundation Awards for their work in biological sciences.

Tom Maniatis, the Isidore S. Edelman Professor of Biochemistry and chair of the Department of Biochemistry and Molecular Biophysics at Columbia University Medical Center, will receive the 2012 Lasker-Koshland Special Achievement Award in Medical Science. Maniatis is known for both his research on the mechanisms of gene regulation and his Molecular Cloning Manual. The award, which he will share with the Carnegie Institutions Donald Brown, is given to scientists for exceptional leadership and citizenship in biomedical science.

I am deeply honored to receive the Lasker Special Achievement Award in Medical Science, said Maniatis. I became a scientist because of the excitement of making discoveries, but to see the impact of these discoveries on the treatment of human disease has been particularly gratifying.

On the Morningside campus, Michael Sheetz, the William R. Kenan Jr. Professor of Biological Sciences, won the Lasker Basic Medical Research Award for his part in discoveries concerning cytoskeletal motor proteins, machines that move cargos within cells, contract muscles, and enable cell movements. The basic research award is given to those scientists whose techniques or concepts to the elimination of major causes of disability and death, according to the Lasker Foundation.

He won it with two other scientists, Stanford Universitys James Spudich and Ronald Vale of the University of California, San Francisco, with whom hes been working for many years. I am deeply honored to receive the Lasker with friends and wish to thank the many people in my lab and our collaborators who contributed so much to the overall effort, said Sheetz.

The Lasker Awards, which carry an honorarium of $250,000 for each category, will be presented at a ceremony on Friday, September 21, in New York City. Since the inception of the Lasker Awards in 1945, 81 Lasker laureates have gone on to win the Nobel Prize, 29 in the last two decades.

Link:
Two Columbia Professors Win Lasker Foundation Awards for Their Work in Biological Sciences

UCLA Chemist Steven G. Clarke Named to Endowed Chair in Gerontology

Removing molecular 'garbage' may be key to successful aging, Clarke says

(Attention editors: Photo Attached)

Newswise Steven G. Clarke, a distinguished professor in the department of chemistry and biochemistry in UCLA's College of Letters and Science, has been named to UCLA's Elizabeth and Thomas Plott Chair in Gerontology.

The endowed chair, held for a five-year term, is intended for a scholar who conducts research and education activities related to aging and longevity in the areas of molecular biology, neuroscience and immunology.

An authority in his field, Clarke focuses on the biochemistry of the aging process and conducts research aimed at understanding, on a molecular level, how human functions are maintained during aging.

His research team has proposed that a major factor in the successful aging of all organisms is how well age-generated molecular "garbage" damaged proteins, nucleic acids, lipids and small molecules can either be repaired or eliminated from the body. His lab has analyzed protein-repair systems and novel types of enzymes that may contribute to reducing this buildup of damage in aging organisms.

Specifically, Clarke's team discovered and characterized the repair system involving the enzyme L-isoaspartyl methyltransferase, or PCMT. Early research on this enzyme's ability to repair defective proteins demonstrated that mice lacking sufficient PCMT had a significant increase in the number of damaged proteins in their tissues, particularly in the brain. Deficiencies in this enzyme have been linked to epilepsy and may also play a role in several degenerative diseases.

According to Clarke, understanding such pathways may help spur the future development of interventions to enhance these repair systems in the elderly, helping address declines in muscle strength, lung capacity, mental status, eye-lens clarity, heart output and other losses of function.

Clarke added that we may now be at the tip of the iceberg in our understanding of how many repair activities exist and how these activities may be manipulated for healthy living, particularly with diet and pharmaceuticals.

"I'm excited to accept the appointment to the Plott Chair and to continue our research in this critical field," said Clarke, who also directs UCLA's Cellular and Molecular Biology Training Program.

Read more from the original source:
UCLA Chemist Steven G. Clarke Named to Endowed Chair in Gerontology

Stem Cells Could Be The Next Anti-Aging Fad

Injections of stem cells taken from patients blood may finally banish wrinkles if clinical trials of a new treatment are successful.

For some, wrinkles are seen as a sign of character. For most, they are an unwelcome reminder of ageing.

However, scientists are developing a method that may finally end the need for the routine of treatments and moisturisers used to try to keep facial lines at bay.

The first clinical trials are to begin shortly on a treatment that uses stem cells purified from a patients blood to combat their own wrinkles.

The cells will be injected beneath the skin where they will grow into new skin cells to help restore the elasticity, claims Pharmacells, the Glasgow-based company behind the technology.

Athol Haas, the companys chief executive, said: The skin has a natural elastic property which comes from cells known as fibroblasts.

The ability of the body to produce this elastic material slows down with age because the number of these fibroblasts decrease.

By introducing large numbers of stem cells into the right place, we are increasing the ability of the body to produce this material. It is still in its early stages but we hope to begin phase one trials within the next 12 months.

Until recently, anyone hoping to get rid of their wrinkles had to rely on cosmetic treatments that injected synthetic collagen under the skin as a filler to remove the lines.

Botox has now become popular for cosmetic treatments, where a neurotoxin from the bacteria Clostridium botulinum is injected to immobilise the muscles that can cause wrinkles.

See the original post here:
Stem Cells Could Be The Next Anti-Aging Fad

Grey's star in trouble for posting spoiler

Patrick Dempsey has confirmed reports suggesting he was reprimanded by Grey's Anatomy bosses after giving away plot secrets by posting a photo of a castmate online.

The actor admits he wasn't thinking about the impact of what he was doing when he tweeted shots of Eric Dane on the set of the medical drama.

Dane's character, Mark Sloane, was left for dead at the end of the last season of the medical drama.

In a pre-taped interview with chat show host Ellen DeGeneres, Dempsey explains, "I tweeted some pictures of this season and they were like a spoiler alert. All of the sudden I got all these phone calls from (the network) ABC, like, 'You have to take this picture down!'"

"I was just enthusiastic: 'This is a great image, I should shoot this.'"

But the damage was already done before Dempsey removed the shot of Dane: "Now we know he survives and comes back and he was just napping in between takes."

But Dane is planning an exit from the show - earlier this summer, the actor announced the upcoming ninth season of the show will be his last.

The new season of Grey's Anatomy is set to debut in the US later this month.

Read the rest here:
Grey's star in trouble for posting spoiler

Heavy drinking may lead to stroke earlier in life

Public release date: 10-Sep-2012 [ | E-mail | Share ]

Contact: Rachel Seroka rseroka@aan.com 612-928-6129 American Academy of Neurology

MINNEAPOLIS A new study shows that people who have three or more alcoholic drinks per day may be at higher risk for experiencing a stroke almost a decade and a half earlier in life than those who do not drink heavily. The research is published in the September 11, 2012, print issue of Neurology, the medical journal of the American Academy of Neurology.

"Heavy drinking has been consistently identified as a risk factor for this type of stroke, which is caused by bleeding in the brain rather than a blood clot," said study author Charlotte Cordonnier, MD, PhD, with the University of Lille Nord de France in Lille, France. "Our study focuses on the effects of heavy alcohol use on the timeline of stroke and the long-term outcome for those people."

For the study, 540 people with an average age of 71 who had a type of stroke called intracerebral hemorrhage were interviewed about their drinking habits. Doctors also interviewed the participants or the caregivers or relatives about the participants' drinking habits. A total of 137 people, or 25 percent, were heavy drinkers, which was defined as having three or more drinks per day, or about 1.6 ounces per day of "pure" alcohol.

Participants also underwent CT brain scans and their medical records were reviewed.

The study found that heavy drinkers experienced a stroke at an average age of 60, 14 years before the average age of their non-heavy drinking counterparts. Among people younger than 60 who had a stroke that occurred in the deep part of the brain, heavy drinkers were more likely to die within two years of the study follow-up than non-heavy drinkers.

"It's important to keep in mind that drinking large amounts of alcohol contributes to a more severe form of stroke at a younger age in people who had no significant past medical history," said Cordonnier.

###

The study was supported by the University of Lille Nord de France and the Association for the Development of Research and Innovation the North Pas de Calais (ADRINORD).

See the original post here:
Heavy drinking may lead to stroke earlier in life

The Nose Knows: Gene Therapy Restores Sense of Smell in Mice

Newswise A team of scientists from Johns Hopkins and other institutions report that restoring tiny, hair-like structures to defective cells in the olfactory system of mice is enough to restore a lost sense of smell. The results of the experiments were published online last week in Nature Medicine, and are believed to represent the first successful application of gene therapy to restore this function in live mammals.

An expert in olfaction, Randall Reed, Ph.D., professor of molecular biology and genetics and co-director of the Center for Sensory Biology at the Johns Hopkins Institute for Basic Biomedical Sciences, cautions that researchers are still years away from applying the same therapy in people, and that if and when it comes, it will likely be most effective for those who suffer from anosmia (lack of smell) due to inherited genetic disorders. But our work has already contributed to a better understanding of the cellular factors involved in anosmia, and that will give us insights into other neurological disorders, as well, he says.

The mice used in the current study carried a genetic mutation that destroyed the production of a protein critical for the functioning of cilia in the cells responsible for smell, called olfactory sensory neurons. These specialized cells each display several of the protruding, hair-like structures that contain receptors for odorants. Without functional cilia, the cells become a broken link in the chain of events necessary for proper odor detection in the environment, the researchers explained.

Beginning with a common cold virus, which readily infects the cells of the nasal cavity, researchers replaced some of the viral genes with a corrected version of the defective cilia gene. They then infected smelling-impaired mice with the altered virus, delivering the corrected gene to the olfactory neural cells that needed it.

At the cellular level, scientists saw a restoration of proper chemical signaling between nerve cells after the treated mice were stimulated with various odorants. Perhaps even more indicative of their success, Reed says, was the 60 percent increase in body weight that the mice experienced once they could smell their meals, leading to increased appetite. Many people with anosmia lose weight because aromas play a significant part in creating appetite and food enjoyment.

Researchers are optimistic about the broader implications of this work, Reed notes, because cilia are not only important to olfactory cells, but also to cells all over the body, from the kidney to the eye. The fact that they were able to treat live mice with a therapy that restored cilia function in one sensory system suggests that similar techniques could be used to treat cilia disorders elsewhere.

We also hope this stimulates the olfactory research community to look at anosmia caused by other factors, such as head trauma and degenerative diseases, says senior author Jeffrey Martens, Ph.D., an associate professor of pharmacology at the University of Michigan. We know a lot about how this system works now have to look at how to fix it when it malfunctions.

In addition to Randall Reed from Johns Hopkins, the papers authors include Jeffrey Martens, Jeremy McIntyre, Ariell Joiner, Corey Williams, Paul Jenkins, Dyke McEwen, Lian Zhang and John Escobado from the Martens Lab at the University of Michigan; Erica Davis, I-Chun Tsai and Nicholas Katsanis from Duke University; Aniko Sabo, Donna Muzny and Richard Gibbs from the Baylor College of Medicine; Eric Green and James Mullikin from the National Institutes of Health Intramural Sequencing Center; Bradley Yoder from the University of Alabama-Birmingham; Sophie Thomas and Tania Atti-Bitach from LUniversit Paris Descartes; Katarzyna Szymanska and Colin A. Johnson from St. Jamess University Hospital in Leeds, UK; and Philip Beales from University College London, UK.

The study was funded by the National Institutes of Health: National Institute on Deafness and Other Communication Disorders (#R01DC009606, F32DC011990, R01DC004553, R01DC008295), National Institute of Diabetes and Digestive and Kidney Diseases (#R01DK75996, R01DK072301, R01DK075972, DK074083), National Institute of Child Health and Human Development (#R01HD042601), and National Eye Institute (#R01EY021872). Additional funding sources included LAgence Nationale de la Recherche and the European Communitys Seventh Framework Programme.

On the Web:

Continued here:
The Nose Knows: Gene Therapy Restores Sense of Smell in Mice

BIO Pacific Rim Summit to Address Algae’s Role in Replacing Fossil Fuels

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organizations (BIO) 2012 Pacific Rim Summit on Industrial Biotechnology and Bioenergy will feature two breakout sessions focusing on commercial applications for algae and advances in algal biomass production and processing. The Summit will bring together industry leaders, university researchers and venture capitalists to facilitate networking and business partnerships this October 9-12 at the Westin Bayshore in Vancouver, Canada.

Algae-produced oils hold the potential for replacing fossil fuel resources in many products. Algae derived starches, oils and proteins can be used in food, animal feed or nutrition supplements, and fatty acids from algae can be used in diesel biofuels as well.

Volatile pricing for fossil fuels, political instability in petroleum producing regions, and the environmental impacts of fossil fuels are some of the key reasons that producers of chemicals and plastics are searching for alternative, renewable resources like algae, said Brent Erickson, executive vice president for BIOs Industrial & Environmental Section. The continued progress in advancing algae, among other feedstocks, toward commercial applications is a vital step in building a growing biobased economy that can strengthen economic security and enhance energy security.

Featured breakout sessions include:

Microalgae: Advancing to Commercial Applications Thursday, October 11, 4 - 5:30pm

Advances in Algal Biomass Production and Processing Friday, October 12, 8:30-10am

Registration is now open.

Media registration is now open and available. Complimentary media registration is available to editors and reporters with valid press credentials working full time for print, broadcast or web publications.

Now in its seventh year, the Pacific Rim Summit on Industrial Biotechnology and Bioenergy will address the latest issues in industrial biotechnology, including algae, advanced biofuels, biopolymers and bioplastics, dedicated energy crops, green chemistry, and synthetic biology. The annual Pacific Rim Summit is the original conference dedicated solely to growth of the industrial biotechnology sector in Asia and the Americas. Visit http://bio.org/pacrim.

Read more from the original source:
BIO Pacific Rim Summit to Address Algae’s Role in Replacing Fossil Fuels

Dr. Tom Maniatis honored with 2012 Lasker-Koshland Special Achievement Award in Medical Science

Public release date: 10-Sep-2012 [ | E-mail | Share ]

Contact: Karin Eskenazi ket2116@columbia.edu 212-342-0508 Columbia University Medical Center

NEW YORK (September 10, 2012) Tom Maniatis, PhD, the Isidore S. Edelman Professor of Biochemistry and chair of the Department of Biochemistry and Molecular Biophysics at Columbia University Medical Center, is to receive the 2012 Lasker-Koshland Special Achievement Award in Medical Science. Dr. Maniatis is known for both his research on the mechanisms of gene regulation and his Molecular Cloning Manual. Dr. Maniatis will receive the award on Sept. 21 in New York City.

"I am deeply honored to receive the Lasker Special Achievement Award in Medical Science," said Dr. Maniatis. "I became a scientist because of the excitement of making discoveries, but to see the impact of these discoveries on the treatment of human disease has been particularly gratifying."

"Tom Maniatis' work is the quintessential example of the path from basic science to clinical applications," said Lee Goldman, MD, executive vice president of Columbia University and dean of the faculties of health sciences and medicine at Columbia University Medical Center. "His cloning manual is used by researchers worldwide, while his research contributions are at the foundation of current thinking about genetics."

In 1980 James Watson, PhD, director of Cold Spring Harbor Laboratory (CSHL), asked Maniatiswho was on the Harvard faculty at the timeto teach new genetic engineering techniques during a summer course at CSHL and then to produce a manual. The resultant Molecular Cloning Manualpublished in 1982 and often referred to as "the Bible" by students and researcherscontained practically every technique biologists needed to manipulate DNA.

Scientists could now identify genes that cause disease and then produce new drugs such as human insulin; and the techniques were indispensable for the success of the Human Genome Project. Dr. Maniatis' laboratory developed many of the techniques in the manual, which he coauthored with his postdoctoral fellow Ed Fritsch, PhD, and Joe Sambrook, PhD, the scientific director at CSHL.

Using the new techniques, Dr. Maniatis was the first to isolate a human gene and to use the cloned gene to identify deletion and substitution mutations that cause disease. The gene beta globin, for example, is part of the hemoglobin complex, and the mutations Dr. Maniatis identified cause a blood disease called beta thalassemia.

Maniatis also created the first complete human "genomic" DNA librarya collection of DNA containing every human genewhich made it possible to isolate and study any human gene. As with his genetic engineering techniques, Maniatis freely shared this library with other researchers.

In other research, Dr. Maniatis and his students uncovered important details of how information in genes is turned into proteins, including the mechanisms of transcription and RNA splicing.

See original here:
Dr. Tom Maniatis honored with 2012 Lasker-Koshland Special Achievement Award in Medical Science